# Evaluating the Levels of Calprotectin in Patients with Chronic Non-specific Colitis: A Brief Report

- 3 Running title: Response to Mesalamine in Patients with Chronic Non-specific Colitis 4 Evaluated by Assessment of Calprotectin Level 5 Authors: Rahmatollah Rafiei<sup>1</sup>, Amin Najjar Khodabakhsh<sup>1</sup>, Fereshteh Rafiei<sup>1</sup>, Amirhossein 6 Kamyab<sup>2</sup>\*, Alireza Ebrahimi<sup>3</sup>, Soheil Ashkani-Esfahani<sup>3</sup> 7 8 9 1-Faculty of Medicine, Islamic Azad University of Najafabad, Najafabad, Iran 2-10 Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran 3-11 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, 12 Iran 13 14 \* Corresponding author: Amirhossein Kamyab, M.D 15 Address: Faculty of Medicine, Fasa University of Medical Sciences, Fasa, Iran 16 Email: ahkamiab@gmail.com 17 18 **Competing Interest** 19 The authors declare that there is no conflict of interest regarding the publication of this paper. 20 Funding 21 The authors received no financial support for the research and authorship.
- 22

## 1 Abstract

Background: Patients with gastrointestinal symptoms of chronic diarrhea, chronic constipation, and abdominal pain might have unspecified signs and symptoms making them hardly characterized. These patients could be labeled as chronic nonspecific colitis patients. In this investigation, we aimed to compare the therapeutic effects of mesalamine in chronic nonspecific colitis patients with by measuring the levels of fecal calprotectin and assessing the reduction of their symptoms during the treatment.

Methods: Eighty-four outpatients (42 patients with normal, and 42 having high calprotectin
levels) participated in this study. Participants were being treated by 2 grams of mesalamine
for one month, and they were evaluated weekly. After one month, the participants' signs and
symptoms were reviewed, and the patients were labeled as treated or untreated.

12 **Results:** The result of this study demonstrated that there was no significant difference 13 between the level of calprotectin among male or female participants, patients with different 14 ages, or patients with different symptoms. Calprotectin levels were significantly different 15 between patients who positively responded to mesalamine treatment compared to those who 16 did not (p<0.001). On the other hand, patients with high calprotectin levels had a higher 17 response rate to mesalamine (94.5%), compared to those with normal calprotectin levels 18 (36.1%; p<0.001).

19 Conclusion: There was a significant correlation between the level of fecal calprotectin and 20 the response rate of the patients to mesalamine; therefore, this parameter might be a good 21 indicator to be used for treatment plans. Further studies are suggested to affirm this outcome.

22

Keywords: Chronic Nonspecific Colitis, Inflammatory Bowel Disease, Calprotectin,
 Predictor, Mesalamine

1

## 2 1. Introduction

3 Non-specific colitis (NSC) refers to a condition in which clinical information is insufficient 4 for a definitive diagnosis despite microscopic evidence of inflammation in the large intestine 5 [1]. NSC patients sometimes present symptoms such as diarrhea, constipation, or abdominal 6 pain [1]; however, they cannot be classified as inflammatory bowel disease (IBD) or irritable 7 bowel syndrome (IBS) [2, 3]. The incidence of NSC is globally increasing; although its 8 pathogenesis and treatment remain obscure, it is sometimes misdiagnosed and mistreated 9 even after a thorough endoscopy and colonoscopy, leading to more severe conditions [2, 4, 10 5]. Therefore, finding a reliable biomarker in order to plan treatment for the disease remains a 11 concern.

Beside radiological, macroscopic, and histological evaluations of the small bowel and colon, 12 there are biochemical markers that can be used as indicators of gastrointestinal (GI) 13 14 inflammation, for instance, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), 15 and orosomucoid levels [6]. Fecal markers such as calprotectin and lactoferrin, have higher 16 specificity for the diagnosis of GI diseases in comparison with serological markers [7-11]. 17 Fecal calprotectin is used as a determinant for grading intestinal inflammation and predicting 18 IBD flares [7-11]. It has been asserted that in contrast with ESR, CRP, or orosomucoid which 19 cannot predict IBD flares, fecal calprotectin has about 70% sensitivity and specificity for 20 prediction of IBD relapses [12].

In this investigation, we aimed to compare the response rate to treatment with mesalamine in NSC patients with high and normal levels of fecal calprotectin and assess the reduction of their symptoms during the treatment.

# 24 **2. Methods**

## 25 2.1.Study Design and Population

26 In this longitudinal study, 500 patients who were referred to the gastroenterology department 27 of Shariati hospital, Isfahan, Iran, between October 2018 and October 2019, and were 28 suspicious of inflammatory bowel disease according to colonoscopic findings were evaluated. 29 Specimens obtained from IBD patients who had colonoscopy indication, and were examined 30 by an expert pathologist. The diagnosis of NSC was based on microscopic evaluation of 31 biopsies. The specimens showing the inflammation of the tissue but could not be classified as 32 IBD were labeled as NSC [13, 14]. Fecal calprotectin levels were also measured in the 33 participants. The cutoff point for the calprotectin level was specified  $\geq 50 \ \mu g/g$  feces 34 according to previously published studies [15]. In the end, 42 patients with normal 35 calprotectin levels (calprotectin of  $<50 \ \mu g/g$ ) and 42 individuals with high fecal calprotectin 36 levels (calprotectin of  $\geq 50 \ \mu g/g$ ) were recruited and allocated into group 1 and group 2, 37 respectively.

38 2.2.Inclusion and Exclusion Criteria

1 Inclusion criteria were clinical and pathological confirmation of NSC according to 2 colonoscopic and pathologic findings, and not having used mesalamine in a month prior to 3 the study. Exclusion criteria were the presence of rectorrhagia as it can disrupt the 4 calprotectin test, a positive history of other confirmed GI diseases such as IBS, Celiac, GI 5 food allergies, autoimmune GI disorders, chronic liver diseases, positive history of recent 6 antibiotic consumption, alcohol abuse, smoking, occurrence of side effects during the 7 treatment, and patients' unwillingness to participate in the study.

## 8 *2.3.Procedure*

9 Patients with normal and high fecal calprotectin levels were being treated by 2 grams (1 gr, 10 twice daily) of mesalamine (500 mg enteric-coated tablet, Arya Pharmaceutical Company, 11 Tehran, Iran) for one month. Every two weeks (days 0, 15, and 30), physical examination of 12 the participants was done by an expert gastroenterologist and a previously designed 13 questionnaire evaluating their abdominal pain through a 10-point scale, frequency and 14 intensity of symptoms, and their overall score for quality of life, was asked to fill. The 15 patients were labeled as responsive or non-responsive to the treatment according to earlier 16 published literature and based on Rome IV criteria [16].

## 17 2.4. Statistical Analysis

After data gathering, the results were analyzed using SPSS statistical software (ver. 18.0, IBM<sup>TM</sup>, USA). The statistical analyses were carried out by employing independent t-test, and P < 0.05 was considered statistically significant.

## 21 2.5. Ethical Considerations

The study's protocol was approved by the Medical Ethics Committee of Islamic Azad University of Najafabad, Isfahan, Iran (Reg. No: ir.iau.najafabad.rec.1396.79). Before the study, a written informed consent was obtained from all participants, and their anonymity was guaranteed.

## 26 **3. Results**

According to the results of this study, no significant difference was witnessed between thetwo groups of the study in terms of age and gender (Table-1).

As shown in Table 2, there were no significant difference between two groups regarding the frequency of gastrointestinal symptoms, including abdominal pain as the most predominant

31 symptom, diarrhea, and constipation.

According to the results, there was a significant difference between the two groups regarding their response to treatment with mesalamine. Patients having high fecal calprotectin levels (Group 2) showed better overall improvement compared to patients with normal calprotectin levels (Group 1) (p<0.001). However, regarding the symptoms, only abdominal pain showed significantly better relief in group 2 compared to group 1 (Table 3). No significant 1 differences were seen regarding the response of diarrhea and constipation to treatment with

2 mesalamine.

3

#### 4 4. Discussion

5 This study was designed to evaluate clinical symptoms of NSC patients having high and 6 normal fecal calprotectin levels in response to treatment with mesalamine. To the best of our 7 knowledge, no study have evaluated fecal calprotectin levels in patients who are being treated 8 with the diagnosis of NSC; however, some investigations examined the biomarker in other 9 diseases such as ulcerative colitis and colonic diverticular diseases [17, 18].

10 Our study showed NSC cases with higher fecal calprotectin levels who received mesalamine 11 as the treatment has a better response rate compared to those with normal levels of 12 calprotectin regarding their clinical symptoms. Previous studies demonstrated the same 13 conclusion in patients with UC as fecal calprotectin found to be significantly lower in 14 patients with clinical and endoscopic remission during mesalamine suppository treatment 15 [17]. Researchers also suggested that the increment of mesalamine dose could decrease fecal 16 calprotectin concentration in UC patients which could be because of a reduction in the tract 17 inflammation [19]. Previous investigations asserted that fecal calprotectin is an indicator of 18 treatment and a predictor of relapse in patients with bowel inflammation [20]. According to 19 our results, this biomarker could also be used as an indicator to predict the response rate to 20 the treatment in NSC patients. Husebye et al. reported that fecal calprotectin has negative 21 predictive value in the case of colonic inflammation and neoplasm [21]. Moreover, fecal 22 calprotectin was described as a viable tool to predict colonic inflammation in patients with 23 chronic diarrhea [22].

24 The gold standard for diagnosis of NSC is an endoscopic or colonoscopic evaluation with 25 histologic confirmation besides clinical examination. Additional markers such as ESR, CRP, 26 and orsomucoid levels could also be beneficial in case of definite conclusions. Fecal 27 calprotectin concentration assessment is perceived as a practical, non-invasive and cost-28 benefit tool for monitoring bowel inflammation [23, 24]. Considering the lack of literature 29 with respect to using biomarkers in the treatment process of NSC patients our study is among 30 the first papers discussing fecal calprotectin as a beneficial marker for monitoring the 31 treatment process of these patients.

This study had several limitations to be considered. The concrete definition of NSC is yet to be cleared, as there is no specific GI tract structural deformity that describes the condition. Pathologists may label a specimen as NSC when they are not able to classify the pathological changes into a specific type of IBD. There are also probable methodological limitations for this study such as conducting biopsy on incorrect sites.

#### 37 5. Conclusion

1 The present study has shown NSC patients who had high fecal calprotectin levels are more 2 responsive to mesalamine treatment. Abdominal pain was the most abundant symptom 3 among NSC patients and patients with high fecal calprotectin levels showed higher relief rate 4 compared to those with normal calprotectin levels. Further studies are required to establish 5 the cost-benefit and precision of using fecal calprotectin in as a predictor in the treatment of 6 patients suffering from IBD.

#### 7 6. References

- Geboes, K. and V. Villanacci, *Terminology for the diagnosis of colitis*. Journal of
   clinical pathology, 2005. 58(11): p. 1133-1134.
- Kirsner, J.B. and R.G. Shorter, *Recent developments in nonspecific inflammatory bowel disease*. New England Journal of Medicine, 1982. **306**(13): p. 775-785.
- Hanauer, S.B., *Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.* Inflammatory bowel diseases, 2006. 12(suppl\_1): p. S3-S9.
- Park, T., D. Cave, and C. Marshall, *Microscopic colitis: A review of etiology, treatment and refractory disease*. World journal of gastroenterology: WJG, 2015.
   21(29): p. 8804.
- 17 5. Whitehead, R., *Mucosal biopsy of the gastrointestinal tract*. Major problems in pathology, 1979. 3: p. 1-241.
- Gisbert, J., Y. Gonzalez-Lama, and J. Mate, *Role of biological markers in inflammatory bowel disease*. Gastroenterologia y hepatologia, 2007. **30**(3): p. 117-21
   129.
- Vermeire, S., G. Van Assche, and P. Rutgeerts, *Laboratory markers in IBD: useful, magic, or unnecessary toys?* Gut, 2006. 55(3): p. 426-431.
- van der Sluys Veer, I.B., HW Verspaget, CBHW Lamers, A, *Faecal parameters in the assessment of activity in inflammatory bowel disease*. Scandinavian Journal of Gastroenterology, 1999. 34(230): p. 106-110.
- Tibble, J. and I. Bjarnason, *Fecal calprotectin as an index of intestinal inflammation*.
   Drugs Today (Barc), 2001. **37**(2): p. 85-96.
- Vermeire, S., G. Van Assche, and P. Rutgeerts, *C-reactive protein as a marker for inflammatory bowel disease*. Inflammatory bowel diseases, 2004. 10(5): p. 661-665.
- Vermeire, S., G. Van Assche, and P. Rutgeerts, *The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases*. Nature Reviews Gastroenterology
   & Hepatology, 2005. 2(12): p. 580.

- Gisbert, J.P., et al., Fecal Calprotectin and Lactoferrin for the Prediction of
   Inflammatory Bowel Disease Relapse. Inflammatory Bowel Diseases, 2009. 15(8): p.
   1190-1198.
- 4 13. Mantzaris, G., et al., *The role of colonoscopy in the differential diagnosis of acute, severe hemorrhagic colitis.* Endoscopy, 1995. 27(09): p. 645-653.
- 6 14. Nikolaus, S. and S. Schreiber, *Diagnostics of inflammatory bowel disease*.
  7 Gastroenterology, 2007. 133(5): p. 1670-89.
- 8 15. Schoepfer, A.M., et al., Ulcerative Colitis: Correlation of the Rachmilewitz
  9 Endoscopic Activity Index with Fecal Calprotectin, Clinical Activity,C-reactive
  10 Protein, and Blood Leukocytes. Inflammatory Bowel Diseases, 2009. 15(12): p. 185111 1858.
- Palsson, O.S., et al., *Rome IV diagnostic questionnaires and tables for investigators and clinicians.* Gastroenterology, 2016. **150**(6): p. 1481-1491.
- Yamamoto, T., T. Shimoyama, and K. Matsumoto, *Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.* Alimentary Pharmacology & Therapeutics, 2015. 42(5): p. 549-558.
- Tursi, A., et al., *Faecal calprotectin in colonic diverticular disease: a case-control study.* International journal of colorectal disease, 2009. 24(1): p. 49-55.
- Osterman, M.T., et al., *Mesalamine Dose Escalation Reduces Fecal Calprotectin in Patients With Quiescent Ulcerative Colitis.* Clinical Gastroenterology and
   Hepatology, 2014. 12(11): p. 1887-1893.e3.
- 22 20. Konikoff, M.R. and L.A. Denson, *Role of fecal calprotectin as a biomarker of*23 *intestinal inflammation in inflammatory bowel disease*. Inflammatory bowel diseases,
  24 2006. 12(6): p. 524-534.
- Husebye, E., H. Tøn, and B. Johne, *Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm11Fecal calprotectin testing was performed by NycoMed Pharma AS (now Axis-Shield AS).*The American Journal of Gastroenterology, 2001. 96(9): p. 2683-2687.
- 29 22. Limburg, P.J., et al., *Fecal calprotectin levels predict colorectal inflammation among*30 *patients with chronic diarrhea referred for colonoscopy*. The American Journal of
  31 Gastroenterology, 2000. 95(10): p. 2831-2837.
- Lasson, A., et al., *The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.* Journal of Crohn's and Colitis, 2014.
  9(1): p. 26-32.

Mant, D., A framework for developing and evaluating a monitoring strategy.
 Evidence-based medical monitoring: from principles to practice. Oxford (UK):
 Blackwell Publishing, 2008: p. 15-30.

- 4
- 5

# 6 7. Tables

Table 1. Demographic data of patients diagnosed with non-specific colitis with normal (group 1, n=42) and high fecal calprotectin level (group 2, n=42). Data are expressed as mean (standard deviation).

Variable	Group 1	Group 2	P-value	
Age (years)	$45.88 \pm 4.18$	$40.16 \pm 14.4$	0.07	
Gender (M/F)	52.4%/47.6%	40.5%/59.5%	0.28	

7

8

Table 2. The frequency of gastrointestinal symptoms in the two groups of the study.

Symptoms	Group 1	Group 2	P-value	
Abdominal pain	85.7%	88.1%	0.9	
Diarrhea	9.5%	14.3%	0.8	
Constipation	2.4%	0	0.9	

9

Table 3. Response rate of patients diagnosed with non-specific colitis with normal (group 1, n=42) and high fecal calprotectin levels (group 2, n=42) treated with mesalamine.

	Group 1			Group 2			
Symptoms	Total	Non- responsive	Responsive	Total	Non- responsive	Responsive	P-value
Abdominal pain	36	63.9%	36.1%	37	5.5%	94.5%	<0.001
Diarrhea	6	33.3%	66.7%	4	50%	50%	0.083

Constipation	0	0	_	1	0	100%	-
Overall	42	7.9%	94.1%	42	69.1%	30.9%	< 0.001

1